A growing body of research. Parameters still matter.
RLRL is a controlled, repeated exposure to red light with parameters specified in the protocol and device documentation. It is not the name of every red lamp. The database includes RCTs, real-world observations, retinal imaging and safety signals.
Hypotheses investigated include photobiomodulation, choroidal response, and pathways regulating eye growth. Changes in choroidal thickness or short-term axis shortening alone do not explain lasting benefit or safety.
The pivotal multicenter RCT of Jiang et al. appeared in the 2022 volume. Subsequently, comparative studies, post-treatment follow-up, a safety review, and studies from outside China were published. In 2026, a record of multi-center real-world work for up to five years is also available.
Go to full timelineIn the multicenter RCT RLRL, the mean adjusted axis gain at 1 year was 0,13 mm versus 0,38 mm in the control group.
No sham; annual observation, Chinese population. We do not transfer the result to any red light lamps.
Publication, Authors and RestrictionsThe study compares RLRL with atropine 0,01% in a crossover design.
It does not examine the simultaneous use of both methods. The choroidal parameters publication from DOI 10.1007 /s40123- 025-01169-0 describes the initial phase of the same study; We don't double the attempt.
Publication, Authors and RestrictionsThe Australian pilot RCT showed less axis gain in the RLRL group; extends data beyond Chinese populations.
34 children, three withdrawals in the RLRL group, including one due to headache. It does not confirm equal effectiveness in all populations.
Publication, Authors and RestrictionsA Spanish RCT showed greater axis control when RLRL was added to orthokeratology than with orthokeratology alone.
Small, single-center and unblinded trial. This is a combination treatment study, not a European monotherapy RCT RLRL .
Publication, Authors and RestrictionsThe review is not a substitute for checking a specific intervention. The publication date and query end date may vary.
The RLRL safety review included 20 research; 1436 participants received therapy. No permanent vision loss was reported in the analyzed corpus.
Median follow-up 9 months, maximum 24. Two descriptions referred to the same patient. The absence of an observed event does not prove zero risk.
Publication, Authors and RestrictionsCochrane 2025 indicates that pharmacological and optical interventions may reduce progression, but the certainty of results and long-term data are mixed.
Last query 19.02.2024 . Does not include all tests with 2025–2026 ; poorly connected networks do not justify simple product ranking.
Publication, Authors and RestrictionsIMI 2025 organizes optical, pharmacological, environmental and lighting strategies and the state of research on their effects.
Mature technologies and emerging methods have a different evidence base. The inspection is not an individual clinical eligibility assessment of the child.
Publication, Authors and RestrictionsThe three-year real-world study groups by length of treatment, with a median 3,65 year in the longest group. The five-year publication has confirmed metadata; We do not publish its detailed effect estimate without a full assessment of the text. Follow-up after RCT indicates rebound after interruption; does not establish a validated tapering regimen.
OCT, ERG and AOSLO imaging expands knowledge but does not exclude rare events. The corpus remains a description of visual impairment and changes in the outer layers of the retina after Eyerising, with improvement after discontinuation. We separate this signal from the number and duration of follow-up in studies without severe events.
The key RCT of Jiang et al. concerns the Eyerising device and a specific protocol. The AOSLO study describes the laser parameters, but without checking the full-text model we do not assign it to the Eyerising product.
Documentation of contraindications, including concomitant use of atropine, should be checked in the current device manual. The comparison of RLRL versus atropine is not a study of this combination.
Documentation in the related projectMost of the research comes from Asia. The Australian RCT includes 34 children; Spanish 26 and concerns the addition of RLRL for orthokeratology. Safety depends on device, power, optics, exposure and clinical eligibility assessment criteria. The RLRL versus atropine study does not investigate concomitant use.
It can only be considered within the framework of clinical eligibility assessment according to the local availability and documentation of the specific device. Test results are not a substitute for IFU or eye evaluation; they are not instructions for self-exposure to light.
This is a framework for a conversation with a specialist, not an individual treatment plan.
Follow-up of RLRL showed maintenance of the effect in those continuing and rebound in some people after discontinuation.
Second year without re-randomization; only 11 children continued RLRL, 114 with 199 eligible were analyzed. It does not establish verified tapering.
Publication, Authors and RestrictionsBilateral visual impairment and retinal changes have been reported following the use of RLRL; improvement was observed after exposure was discontinued.
The case report is a safety signal, not an indicator of incidence or evidence that all devices have the same risk profile.
Publication, Authors and RestrictionsThe real-world study includes groups with varying durations of RLRL use, including 91 participants treated with 3 for at least one year.
These are groups by length of treatment, not a three-year RCT. Possible selection of continuators. Median in the longest group 3,65 of the year.
Publication, Authors and RestrictionsThe 2026 publication by Zhang et al. describes multicenter real-world data with follow-up dating back to 5 years.
DOI, authors and publication type were verified. Follow-up for 5 years does not mean that each participant was followed for 5 years; this is not a five-year RCT.
Publication, Authors and RestrictionsThe AOSLO study showed no significant loss of cone density or differences in microcirculatory parameters tested after at least 8 months of RLRL.
66 eyes, of which 20 in the RLRL group; the unit is the eye, not the number of patients. Cross-sectional examination does not exclude rare or distant lesions.
Publication, Authors and RestrictionsESO and IMI present a framework for the selection of management, prevention and monitoring of myopia progression.
The guidelines require reference to current knowledge, local availability and the specific patient.
Publication, Authors and Restrictions